Drug Insights

Accessing Ketorolac Information on Synapse: A Step-by-Step Approach

22 February 2024
2 min read

Ketorolac Tromethamine, also known by its trade name Toradol®, is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for the treatment of moderate to severe pain, including pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, and headaches. Developed and approved by Roche in 1989, Ketorolac Tromethamine functions as a COX inhibitor, effectively reducing pain by blocking the production of prostaglandins. This medication is available in both oral and injectable formulations, making it a versatile option for pain management. Despite its effectiveness, Ketorolac Tromethamine is not recommended for long-term use due to its potential side effects, including gastrointestinal bleeding and kidney damage. Click on the image below to begin the exploration journey of Ketorolac through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Otsuka Announces AVP-786 Trial Results for Alzheimer's Agitation
Latest Hotspot
3 min read
Otsuka Announces AVP-786 Trial Results for Alzheimer's Agitation
21 February 2024
Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.
Read →
Maximize Your Synapse Use: Your Guide to Searching Olanzapine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Olanzapine
21 February 2024
Zyprexa® (Olanzapine), an antipsychotic, is commonly used to treat schizophrenia, bipolar 1, and related agitation.
Read →
Alisertib Phase II Trial for Small Cell Lung Cancer Begins: ALISCA-Lung1
Latest Hotspot
3 min read
Alisertib Phase II Trial for Small Cell Lung Cancer Begins: ALISCA-Lung1
20 February 2024
Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.
Read →
Zelenirstat: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
Zelenirstat: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
20 February 2024
Zelenirstat, an effective oral NMT inhibitor, showed promising results in treating advanced relapsed/refractory cancer at 2024's ASCO_GI.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.